Exelixis, Inc. (FRA:EX9)

Market Cap	9.62B +4.6%
Revenue (ttm)	1.98B +7.0%
Net Income	666.51M +50.1%
EPS	2.37 +58.0%
Shares Out	n/a
PE Ratio	14.43
Forward PE	12.49
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	28
Open	37.27
Previous Close	37.35
Day's Range	37.27 - 37.27
52-Week Range	29.41 - 44.40
Beta	n/a
RSI	54.52
Earnings Date	May 5, 2026

About Exelixis

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF recep...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1994
• Employees: 1,077
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: EX9

Financial Performance

In 2025, Exelixis's revenue was $2.32 billion, an increase of 6.98% compared to the previous year's $2.17 billion. Earnings were $782.57 million, an increase of 50.13%.

Financial numbers in USD